Dermapharm Holding SE
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMPHF research report →
Companywww.dermapharm.de
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products.
- CEO
- Hans-Georg Feldmeier
- IPO
- 2022
- Employees
- 3,610
- HQ
- Grünwald, DE
Price Chart
Valuation
- Market Cap
- $1.96B
- P/E
- 18.44
- P/S
- 2.09
- P/B
- 3.60
- EV/EBITDA
- 9.80
- Div Yield
- 1.82%
Profitability
- Gross Margin
- 42.74%
- Op Margin
- 20.01%
- Net Margin
- 12.34%
- ROE
- 21.44%
- ROIC
- 8.55%
Growth & Income
- Revenue
- $1.16B · -1.37%
- Net Income
- $132.36M · 16.32%
- EPS
- $2.46 · 16.59%
- Op Income
- $221.66M
- FCF YoY
- -14.59%
Performance & Tape
- 52W High
- $59.00
- 52W Low
- $39.56
- 50D MA
- $39.56
- 200D MA
- $39.56
- Beta
- 0.86
- Avg Volume
- 215.2
Get TickerSpark's AI analysis on DMPHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DMPHF Coverage
We haven't published any research on DMPHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DMPHF Report →